<DOC>
	<DOC>NCT02702492</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).</brief_summary>
	<brief_title>PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)</brief_title>
	<detailed_description>This is a first-in-human, multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies (including sarcoma, colon, lung, etc.) or NHL for which all standard therapeutic options considered useful by the investigator have been exhausted.</detailed_description>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Advanced solid malignancies or NHL for which all standard therapeutic options considered useful have been exhausted. Must have objective evidence of progressive disease on study entry. Advanced solid malignancies: Measureable disease as defined by RECIST 1.1. NHL: Measureable disease including target lesion(s) as defined by the Lugano Classification for initial evaluation and staging. Must have a site of disease amenable to biopsy and be a candidate for biopsy. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1. Dose Expansion Phase (KPT9274 + niacin ER cohort only): Patient tumors NAPRT1 and IDH1 tumor status must be determined at the central laboratory prior to enrollment. Life expectancy of ≥3 months. Known central nervous system (CNS) disease or leptomeningeal involvement, regardless of response to prior therapy. Major surgery within 4 weeks before C1D1. Active infection with completion of therapeutic antibiotics, antivirals, or antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or antifungals are permitted. Known history of Human Immunodeficiency Virus (HIV); HIV testing is not required as part of this study. Known, active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen). Significant diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea that could interfere with the absorption of KPT9274. Active peptic ulcer disease or other active gastrointestinal bleeds.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PAK4</keyword>
	<keyword>KPT-9274</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>NHL</keyword>
	<keyword>solid tumors</keyword>
</DOC>